Magnetar Financial LLC → Astria Therapeutics, Inc.

Since the filing of the Schedule 13D on October 24, 2025, on January 23, 2026, the Issuer consummated a merger (the "Merger") pursuant to which each issued and outstanding Share was cancelled and converted into the right to receive $8.55 in cash, without interest. In connection with the Merger, the Reporting Persons' 3,431,007 Shares, which consisted of 1,560,502 Shares sold for the benefit of PRA Master Fund; 804,159 Shares sold for the benefit of Systematic Master Fund; 221,576 Shares sold for the benefit of the Relative Value Master Fund and 844,770 Shares sold for the benefit of two Managed Accounts, were cancelled and converted into the right to receive $8.55 in cash, without interest.